Kurisu S, Fujiwara H
Cureus. 2025; 17(2):e78752.
PMID: 40070618
PMC: 11893912.
DOI: 10.7759/cureus.78752.
Ikegami Y, Kitagawa T, Sada Y, Okamoto D, Hamamoto K, Tatsugami F
Circ Rep. 2025; 7(3):198-206.
PMID: 40066220
PMC: 11890280.
DOI: 10.1253/circrep.CR-24-0170.
Castiglione V, Montuoro S, Orlando G, Aimo A, Vergaro G, Emdin M
Eur Heart J Suppl. 2025; 27(Suppl 1):i88-i97.
PMID: 39980786
PMC: 11836727.
DOI: 10.1093/eurheartjsupp/suae111.
Usuku H, Yamamoto E, Miyazaki K, Higashi R, Nozuhara A, Oike F
Eur Heart J Imaging Methods Pract. 2025; 3(1):qyae113.
PMID: 39831277
PMC: 11740316.
DOI: 10.1093/ehjimp/qyae113.
Yu A, Chen Y, Tsai C, Chao C, Su M, Shun C
Eur J Nucl Med Mol Imaging. 2025; .
PMID: 39800807
DOI: 10.1007/s00259-025-07079-4.
2025 Update Consensus of Tc-Pyrophosphate Scintigraphy in the Transthyretin Cardiac Amyloidosis from the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.
Wang S, Huang Y, Chen Y, Tsai C, Ko C, Lin Y
Acta Cardiol Sin. 2025; 41(1):55-71.
PMID: 39776923
PMC: 11701493.
DOI: 10.6515/ACS.202501_41(1).20241027A.
Computed Tomography Evaluation of Extracellular Volume for Predicting Prognosis in Patients with Severe Renal Dysfunction on Dialysis.
Goto H, Takaoka H, Ota J, Noguchi Y, Nishikawa Y, Matsumoto M
J Clin Med. 2025; 13(24.
PMID: 39768483
PMC: 11728230.
DOI: 10.3390/jcm13247561.
Echocardiographic findings of patients with transthyretin amyloid cardiomyopathy.
Usuku H, Oike F, Kuyama N, Hirakawa K, Takashio S, Izumiya Y
J Echocardiogr. 2024; 23(1):1-9.
PMID: 39729212
DOI: 10.1007/s12574-024-00672-w.
Extracellular Volume by Computed Tomography Is Useful for Prediction of Prognosis in Dilated Cardiomyopathy Cases with Heart Failure with Reduced Ejection Fraction.
Yashima S, Takaoka H, Ota J, Matsumoto M, Nishikawa Y, Noguchi Y
J Cardiovasc Dev Dis. 2024; 11(12).
PMID: 39728289
PMC: 11676668.
DOI: 10.3390/jcdd11120399.
Long-Term Outcomes of Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy in Two Patients.
Kuyama N, Izumiya Y, Takashio S, Tabira A, Hanatani S, Usuku H
JACC Case Rep. 2024; 29(22):102771.
PMID: 39691895
PMC: 11646908.
DOI: 10.1016/j.jaccas.2024.102771.
Atrial Lesion and Diastolic Dysfunction May Be Associated With Atrial Fibrillation in Patients With Cardiac Amyloidosis.
Otsuka K, Kawano H, Koike H, Sueyoshi E, Arakawa S, Fukae S
Circ Rep. 2024; 6(12):539-546.
PMID: 39659638
PMC: 11626019.
DOI: 10.1253/circrep.CR-24-0116.
A Quantitative Diagnostic Method Using Tc-pyrophosphate Lateral Planar Images to Distinguish Between Transthyretin Amyloid Cardiomyopathy and False-Positive Images Due to Blood Pools.
Hara J, Ishii S, Kobiyama H, Fukushima K, Kawamoto N, Yamakuni R
Ann Nucl Cardiol. 2024; 10(1):23-28.
PMID: 39635326
PMC: 11612392.
DOI: 10.17996/anc.24-00001.
Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration.
Nagai T, Horinouchi H, Hashimoto K, Ijichi T, Yoshioka K, Ikari Y
Int J Cardiovasc Imaging. 2024; 41(1):93-101.
PMID: 39607611
DOI: 10.1007/s10554-024-03293-7.
Single-center analysis of cardiac amyloidosis using 99m Tc-HMDP imaging for diagnosis and evaluation after tafamidis treatment.
Egi R, Matsusaka Y, Watanabe K, Seto A, Matsunari I, Arai T
Nucl Med Commun. 2024; 46(1):38-46.
PMID: 39483085
PMC: 11634134.
DOI: 10.1097/MNM.0000000000001922.
Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions.
Kim S, Lee S, Oh J, Lee C, Hwang S, Kang W
Sci Rep. 2024; 14(1):22863.
PMID: 39354040
PMC: 11445427.
DOI: 10.1038/s41598-024-74191-0.
The APOA1 p.Leu202Arg variant potentially causes autosomal recessive cardiac amyloidosis.
Yagi S, Miyamoto R, Tasaki M, Morino H, Otani R, Kadota M
Hum Genome Var. 2024; 11(1):30.
PMID: 39152105
PMC: 11329782.
DOI: 10.1038/s41439-024-00288-7.
Deep vein thrombosis in a patient with wild-type transthyretin cardiac amyloidosis.
Kurisu S, Fujiwara H
J Cardiol Cases. 2024; 29(5):218-221.
PMID: 39100518
PMC: 11295011.
DOI: 10.1016/j.jccase.2024.01.005.
Importance of fourth heart sound and preserved left atrial function in wild-type transthyretin amyloidosis.
Ochi Y, Yamasaki N, Kubo T, Baba Y, Miyagawa K, Noguchi T
ESC Heart Fail. 2024; 11(6):4000-4008.
PMID: 39090841
PMC: 11631332.
DOI: 10.1002/ehf2.14937.
Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis.
Kourek C, Briasoulis A, Magouliotis D, Georgoulias P, Giamouzis G, Triposkiadis F
World J Cardiol. 2024; 16(7):370-379.
PMID: 39086890
PMC: 11287460.
DOI: 10.4330/wjc.v16.i7.370.
Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis.
Kwok C, Choy C, Pinney J, Townend J, Whelan C, Fontana M
ESC Heart Fail. 2024; 11(6):3901-3910.
PMID: 39041492
PMC: 11631279.
DOI: 10.1002/ehf2.14975.
